Prof. Qiang Zhang 张强
Chief Physician, Professor
Department of Breast Surgery, Liaoning Cancer Hospital & Institute, Shenyang
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Early diagnosis and surgical treatment of breast tumors, including mastectomy, breast-conserving surgery, minimally invasive procedures, sentinel lymph node biopsy, and immediate or delayed breast reconstruction. Comprehensive management of complex cases.
Dr. Zhang is Director of the Fourth Breast Ward, Professor, and Chief Physician. Training includes fellowships at MD Anderson Cancer Center (2009–2010) and the European Institute of Oncology (2013). Dr. Zhang performs subcutaneous mastectomy, sentinel lymph node biopsy, and breast reconstruction using prostheses or autologous tissue.
Professional roles
- Member, Chinese Medical Association
- Member, Breast Oncology Group, Oncology Branch, Chinese Medical Association
- Member, Breast Cancer Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Breast Disease Professional Committee, China Medicine Education Association
Name order: in Chinese the family name comes first (Zhang Qiang). Papers usually list the name as Qiang Zhang or Zhang Q.
Selected publications
29 papers on PubMed matched by name and affiliation; 12 as first or senior author since 2016. Most recent first- or senior-author papers:
- Signal Transduct Target Ther, 2025 (first author): Efficacy, safety and exploratory analysis of neoadjuvant tislelizumab (a PD-1 inhibitor) plus nab-paclitaxel followed by epirubicin/cyclophosphamide for triple-negative breast cancer: a phase 2 TREND trial. PubMed 40414961
- Exp Cell Res, 2022 (senior author): SEZ6L2, regulated by USF1, accelerates the growth and metastasis of breast cancer. PubMed 35523305
- Front Public Health, 2022 (senior author): Research Progress on Influencing Factors and Intervention Measures of Post-traumatic Growth in Breast Cancer Patients. PubMed 35801243
- Pathol Oncol Res, 2021 (senior author): Quantification of Ki67 Change as a Valid Prognostic Indicator of Luminal B Type Breast Cancer After Neoadjuvant Therapy. PubMed 34987312
- Endocr Relat Cancer, 2021 (senior author): Leptin-elicited PBX3 confers letrozole resistance in breast cancer. PubMed 33608482
- Cancer Res Treat, 2019 (senior author): Upregulation of PITX2 Promotes Letrozole Resistance Via Transcriptional Activation of IFITM1 Signaling in Breast Cancer Cells. PubMed 30025446
- Cancer Med, 2018 (senior author): Interaction between glutathione S-transferase M1-null/present polymorphism and adjuvant chemotherapy influences the survival of breast cancer. PubMed 30032483
- J Thorac Dis, 2018 (senior author): The effect of delayed adjuvant chemotherapy on relapse of triple-negative breast cancer. PubMed 29997947
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion